Continued Role for Transplantation in NDMM
Before closing out his discussion on newly diagnosed multiple myeloma, Ajay K. Nooka, MD, MPH, FACP, emphasizes the continued role of transplantation in this setting.
Newly Diagnosed MM: Optimizing Maintenance Therapy and Managing Toxicities
Ajay K. Nooka, MD, MPH, FACP, shares insight on strategies to optimally deliver maintenance therapy and manage toxicities in patients with multiple myeloma.
Importance of Depth of Response and Treatment Duration in NDMM
Considerations for assessing treatment response and electing to continue therapy in patients with newly diagnosed multiple myeloma.
Isa-VRd in NDMM: Results From the GMMG-HD7 Study
Insight on the role of isatuximab and VRd in patients with newly diagnosed multiple myeloma following data from the GMMG-HD7 study.
Dara-KRd in NDMM: Results From the MASTER Study
Shifting his focus to the MASTER study in newly diagnosed multiple myeloma, Ajay K. Nooka, MD, MPH, FACP, highlights the role of daratumumab with KRd.
Dara-RVd in NDMM: Updates from the GRIFFIN Study
Expert perspectives on the use of daratumumab with RVd in patients with newly diagnosed multiple myeloma in the context of updates from the GRIFFIN study.
A Case of Newly Diagnosed Multiple Myeloma
Expert hematologist-oncologist Ajay K. Nooka, MD, MPH, FACP, shares his perspective on the management of a woman newly diagnosed with multiple myeloma.
Addition of Daratumumab to 3-Agent Regimens Deepens Response to Therapy, According to Nooka
During a Targeted Oncology virtual event, Ajay K. Nooka, MD, MPH discussed the case of a patient with stage II multiple myeloma.
